Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469; D10829
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII 003N66TS6T
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza like illness08.01.03.0100.003572%
Inguinal hernia07.16.02.0010.002436%-
Insomnia17.15.03.002; 19.02.01.0020.013639%
Interstitial lung disease10.02.01.033; 22.01.02.0030.001624%-
Intestinal obstruction07.13.01.0020.001624%-
Lactic acidosis14.01.01.0020.002436%-
Loss of consciousness17.02.04.0040.008119%-
Lymphadenopathy01.09.01.0020.001624%-
Malignant melanoma16.03.01.001; 23.08.01.0010.002436%-
Marasmus14.03.02.0130.007307%-
Melaena07.12.02.004; 24.07.02.0130.001624%-
Mental impairment17.03.03.002; 19.21.02.0030.001624%-
Metabolic acidosis14.01.01.0030.002436%-
Movement disorder17.01.02.0100.005196%-
Muscle rigidity15.05.04.001; 17.05.02.0050.002436%-
Musculoskeletal pain15.03.04.0070.004059%
Myocardial ischaemia02.02.02.008; 24.04.04.0100.001624%-
Neoplasm malignant16.16.01.0010.004871%-
Neuroendocrine carcinoma of the skin05.08.01.009; 16.03.02.008; 23.08.02.0080.001624%-
Neurogenic bladder17.10.01.002; 20.03.03.0010.001624%-
Nightmare19.02.03.0030.001624%-
Obsessive-compulsive disorder19.06.05.0020.001624%-
Obsessive-compulsive personality disorder19.05.04.0010.001624%-
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.0110.002436%
On and off phenomenon17.01.05.0040.002436%-
Orthostatic hypotension17.05.01.020; 24.06.03.0040.024518%-
Panic attack19.06.04.0010.002436%-
Parkinsonism17.01.05.0030.006008%-
Pemphigoid10.04.02.002; 23.03.01.0040.001624%-
Personality change17.02.05.019; 19.05.01.0060.001624%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages